Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Taysha Gene Therapies (TSHA) Asset Writedowns and Impairment (2023 - 2024)

Historic Asset Writedowns and Impairment for Taysha Gene Therapies (TSHA) over the last 2 years, with Q3 2024 value amounting to $4.8 million.

  • Taysha Gene Therapies' Asset Writedowns and Impairment rose 68538.96% to $4.8 million in Q3 2024 from the same period last year, while for Sep 2025 it was $5.3 million, marking a year-over-year change of. This contributed to the annual value of $4.8 million for FY2024, which is 35427.23% up from last year.
  • As of Q3 2024, Taysha Gene Therapies' Asset Writedowns and Impairment stood at $4.8 million, which was up 68538.96% from $449000.0 recorded in Q4 2023.
  • Taysha Gene Therapies' Asset Writedowns and Impairment's 5-year high stood at $4.8 million during Q3 2024, with a 5-year trough of $449000.0 in Q4 2023.